Last $148.64 USD
Change Today -0.04 / -0.03%
Volume 209.0K
IDXX On Other Exchanges
As of 8:10 PM 12/26/14 All times are local (Market data is delayed by at least 15 minutes).

idexx laboratories inc (IDXX) Snapshot

Previous Close
Day High
Day Low
52 Week High
11/13/14 - $153.89
52 Week Low
01/2/14 - $104.64
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

idexx laboratories inc (IDXX) Related Bloomberg News

View More Bloomberg News

idexx laboratories inc (IDXX) Related Businessweek News

No Related Businessweek News Found

idexx laboratories inc (IDXX) Details

IDEXX Laboratories, Inc. develops, manufactures, and distributes products and services primarily for the companion animal veterinary, livestock and poultry, water testing, and dairy markets worldwide. The company operates through Companion Animal Group, Water, Livestock and Poultry Diagnostics, Dairy, and OPTI Medical segments. The company primary offers point-of-care veterinary diagnostic products comprising instruments and consumables, and rapid assays; veterinary reference laboratory diagnostic and consulting services; and practice management systems and services, and digital radiography systems used by veterinarians. It also provides biological materials testing and laboratory diagnostic instruments and services used by the biomedical research community; diagnostic and health-monitoring products for livestock and poultry; products that test water for certain microbiological contaminants; products that test milk for antibiotic residues and other contaminants; and point-of-care electrolytes and blood gas analyzers used in the human point-of-care medical diagnostics market. The company markets and sells its products through marketing, sales, and technical service groups, as well as independent distributors and other resellers. IDEXX Laboratories, Inc. was founded in 1983 and is headquartered in Westbrook, Maine.

5,700 Employees
Last Reported Date: 02/18/14
Founded in 1983

idexx laboratories inc (IDXX) Top Compensated Officers

Chairman, Chief Executive Officer and Preside...
Total Annual Compensation: $784.6K
Executive Vice President
Total Annual Compensation: $396.2K
Executive Vice President
Total Annual Compensation: $396.2K
Executive Vice President
Total Annual Compensation: $396.2K
Vice President of Finance
Total Annual Compensation: $300.0K
Compensation as of Fiscal Year 2013.

idexx laboratories inc (IDXX) Key Developments

IDEXX Laboratories, Inc. Launches New Version of IDEXX-PACS Imaging Software

IDEXX Laboratories, Inc. launched IDEXX-PACS Imaging Software version 4.0. This software will immediately benefit current customers, whose feedback helped inform the company's significant investment toward the software's development. IDEXX Digital Imaging customers can take advantage of an intuitive, user-friendly interface that replaces text with simple icons and lets practices follow their normal work flow in far fewer steps. Clinicians can quickly and easily capture images and manage their cases for more responsive patient care and client service. The IDEXX-PACS 4.0 software is touch-screen enabled so users can easily manipulate images with one hand, including pinch and zoom. Technique settings are viewable within the software and are automatically recorded in the practice's radiology log. And customers gain peace of mind because all images are safely backed up and stored in the cloud using the IDEXX ImageBank Storage System. Additional IDEXX-PACS 4.0 software work-flow improvements include: profiles organized by patient so users can view all studies in one place; a visual shot tree so users can simply click on an area of focus rather than selecting from a list; access to recent cases from the home screen for quick reference; the ability to search images by date, species, doctor or modality and to hide or display historical images, as needed; and a favorites list where shots taken most frequently can be saved for quick access.

IDEXX Laboratories, Inc. Reports Unaudited Consolidated Earnings Results for the Third Quarter and Nine Months Ended September 30, 2014; Revises Earnings Guidance for 2014; Provides Earnings Guidance for the Year 2015

IDEXX Laboratories, Inc. reported unaudited consolidated earnings results for the third quarter and nine months ended September 30, 2014. For the quarter, the company reported revenue of $383,523,000 compared to $338,297,000 a year ago. Income from operations was $72,189,000 compared to $65,485,000 a year ago. Income before provision for income taxes was $68,208,000 compared to $64,478,000 a year ago. Net income attributable to stockholders was $52,142,000 or $1.03 per diluted share compared to $45,688,000 or $0.86 per diluted share a year ago. For the nine months, the company reported revenue of $1,133,848,000 compared to $1,022,985,000 a year ago. Income from operations was $225,454,000 compared to $205,434,000 a year ago. Income before provision for income taxes was $216,693,000 compared to $203,302,000 a year ago. Net income attributable to stockholders was $155,945,000 or $3.03 per diluted share compared to $144,542,000 or $2.66 per diluted share a year ago. Net cash provided by operating activities was $208,543,000 compared to $180,581,000 a year ago. Purchases of property and equipment were $42,504,000 compared to $61,459,000 a year ago. Acquisition of intangible assets was $175,000 compared to $1,024,000 a year ago. The company has updated its organic revenue growth guidance for 2014 to 9.5% to reflect growth trends at the high end of its previous guidance range. Operating margin is expected to be in line with the company's previous guidance of relatively consistent operating margins for the full year compared to 2013. Favorable operating performance, reduced tax expense, and a reduction in outstanding shares are partially offset by unfavorable impacts of foreign exchange, resulting in an increase from previous adjusted EPS guidance of $3.79 to $3.86 to current adjusted EPS guidance of $3.85 to $3.90. The recent strengthening of the US dollar is projected to reduce reported revenues and EPS by approximately $10 million and $0.04, respectively, as compared to prior 2014 outlook. Adjusted revenue will be in the range of $1,505 million to $1,510 million. Free cash flow will be in the range of 100% to 110% of net income. Capital expenditures will be $75 million. EPS will be $3.42 to $3.54. Adjusted EPS growth will be in the range of 12% to 13%. The company expects reported revenues of $1,482,000,000 to $1,492,000,000. The company expects tax rate of 29.0%, excluding benefits from the nonrecurring income tax item noted earlier. Net interest expense for 2014 is now expected to be about $14 million, reflecting recent borrowings. For 2015, the company expected revenue in the range of $1,690 million to $1,710 million, EPS in the range of $4.38 to $4.48. The company's 2015 outlook also reflects an expected effective tax rate of 30.5%.

IDEXX Laboratories, Inc. to Report Q3, 2014 Results on Oct 24, 2014

IDEXX Laboratories, Inc. announced that they will report Q3, 2014 results at 7:00 AM, US Eastern Standard Time on Oct 24, 2014


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
IDXX:US $148.64 USD -0.04

IDXX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
DENTSPLY International Inc $53.84 USD +0.08
Hologic Inc $26.93 USD +0.04
MEDNAX Inc $66.69 USD -0.12
ResMed Inc $57.36 USD -0.03
Cooper Cos Inc/The $164.00 USD -0.19
View Industry Companies

Industry Analysis


Industry Average

Valuation IDXX Industry Range
Price/Earnings 38.7x
Price/Sales 5.0x
Price/Book 31.3x
Price/Cash Flow 35.6x
TEV/Sales 4.1x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact IDEXX LABORATORIES INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at